Status:
RECRUITING
A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)
Lead Sponsor:
Agios Pharmaceuticals, Inc.
Conditions:
Sickle Cell Disease
Eligibility:
All Genders
16+ years
Phase:
PHASE2
Brief Summary
The main purpose of this study is to compare the effect of tebapivat versus placebo on anemia and to detect a dose-response for hemoglobin (Hb) response in participants with SCD.
Eligibility Criteria
Inclusion
- Key
- Documented diagnosis of SCD (HbSS, HbSC \[combined heterozygosity for hemoglobins S and C\], sickle hemoglobin \[HbS\]/β0-thalassemia, HbS/β+-thalassemia, or other sickle cell syndrome variants).
- Hemoglobin ≥5.5 and ≤10.5 grams per decilitre (g/dL). Hemoglobin concentration must be based on an average of at least 2 Hb concentration measurements (separated by ≥7 days) collected during the screening period.
- If taking hydroxyurea, the hydroxyurea dose must be stable for at least 90 days before randomization. Discontinuation of hydroxyurea requires a 90-day washout before providing informed consent.
- Key
Exclusion
- Receiving regularly scheduled red blood cell (RBC) transfusion therapy (also termed chronic, prophylactic, or preventative transfusion); episodic transfusion in response to worsened anemia or vaso-occlusive crisis (VOC) is permitted. Additionally, a participant who requires episodic transfusion(s) may not have received a transfusion(s) within 60 days before providing informed consent or during the screening period.
- \>10 sickle cell pain crisis (SCPCs) in the 12 months before providing informed consent.
- Receiving anabolic steroids that have not been stopped for at least 4 weeks before randomization. Testosterone replacement therapy to treat hypogonadism is allowed; the testosterone dose and preparation must be stable for ≥10 weeks before randomization.
- Hospitalized for an SCPC and/or other vaso-occlusive event within 14 days before providing informed consent or within 14 days before randomization. If an SCPC occurs during the screening period, the screening period may be extended with Medical Monitor approval.
- Receiving treatment with voxelotor, crizanlizumab, or L-glutamine within 90 days before randomization.
- Platelet count \<lower limit of normal (LLN) for the local laboratory or \<150×109/liter (L) (whichever is lower) during screening. Platelet transfusions received within 28 days before consent or during screening.
- Receiving treatment with hematopoietic stimulating agents within 90 days before randomization.
- Prior exposure to gene therapy or prior bone marrow or stem cell transplantation, including any conditioning regimen.
Key Trial Info
Start Date :
May 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2027
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT06924970
Start Date
May 1 2025
End Date
May 1 2027
Last Update
December 26 2025
Active Locations (29)
Enter a location and click search to find clinical trials sorted by distance.
1
UCHealth at University of Colorado Anschutz Medical Campus
Aurora, Colorado, United States, 80045
2
UConn Health
Farmington, Connecticut, United States, 06030-0001
3
Children's National Hospital
Washington D.C., District of Columbia, United States, 20010
4
MedStar Washington Hospital Center
Washington D.C., District of Columbia, United States, 20010